Stemline Therapeutics to Present at the 2016 Wedbush PacGrow Healthcare Conference
August 11 2016 - 7:00AM
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that Ivan
Bergstein, M.D., Stemline’s CEO, will present at the 2016 Wedbush
PacGrow Healthcare conference on Tuesday, August 16, 2016 at 3:40
PM ET. The conference will be held at the Le Parker Meridien in New
York, NY. A live webcast of the presentation can be viewed on the
company’s website at www.stemline.com.
About Stemline Therapeutics Stemline
Therapeutics, Inc. is a clinical stage biopharmaceutical company
developing novel oncology therapeutics. Stemline is developing
three clinical stage product candidates, SL-401, SL-701, and
SL-801. A Phase 2 potentially pivotal trial with SL-401, a targeted
therapy directed to the interleukin-3 receptor (IL-3R; CD123)
present on a wide range of hematologic cancers, is enrolling
patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Data from this ongoing trial have demonstrated high overall
response rates (ORR), with multiple complete responses (CRs).
Patients are being followed for response duration and outcomes, and
new patients continue to enroll into the study. In addition,
ongoing Phase 2 trials with SL-401 are currently enrolling patients
with additional malignancies including acute myeloid leukemia (AML)
in remission with high risk for relapse including minimal residual
disease (MRD) and advanced, high risk myeloproliferative neoplasms
(MPN) of unmet medical need. A Phase 1/2 trial in
relapsed/refractory multiple myeloma with SL-401 in combination
with standard therapies is also enrolling patients. A Phase 2 trial
with SL-701, an immunotherapy designed to activate the immune
system to attack tumors, is currently enrolling adult patients with
second-line glioblastoma multiforme (GBM). A Phase 1 trial with
SL-801, a novel oral small molecule reversible inhibitor of XPO1,
is currently enrolling patients with advanced solid tumors. For
more information about Stemline Therapeutics, visit
www.stemline.com.
Forward-Looking StatementsSome of the
statements included in this press release may be forward-looking
statements that involve a number of risks and uncertainties. For
those statements, we claim the protection of the safe harbor for
forward-looking statements contained in the Private Securities
Litigation Reform Act of 1995. The factors that could cause our
actual results to differ materially include: the success and timing
of our clinical trials and preclinical studies for our product
candidates, including site initiation, internal review board
approval, scientific review committee approval, patient accrual,
safety, tolerability and efficacy data observed, and input from
regulatory authorities; our plans to develop and commercialize our
product candidates; our available cash and investments; our ability
to obtain and maintain intellectual property protection for our
product candidates; our ability to manufacture; the performance of
third-party manufacturers, clinical research organizations,
clinical trial sponsors and clinical trial investigators; and other
risk factors identified from time to time in our reports filed with
the Securities and Exchange Commission. Any forward-looking
statements set forth in this press release speak only as of the
date of this press release. We do not intend to update any of these
forward-looking statements to reflect events or circumstances that
occur after the date hereof.
Contact
Investor Relations
Stemline Therapeutics, Inc.
750 Lexington Avenue
Eleventh Floor
New York, NY 10022
Tel: 646-502-2307
Email: investorrelations@stemline.com
Stemline Therapeutics (NASDAQ:STML)
Historical Stock Chart
From Mar 2024 to Apr 2024
Stemline Therapeutics (NASDAQ:STML)
Historical Stock Chart
From Apr 2023 to Apr 2024